Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis

Table 2 Univariate Cox regression analysis of clinical parameters for OS

Characteristics	Before PSM		After PSM
Characteristics	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years (≤60 vs. > 60)	1.064 (0.877–1.292)	0.528	0.995 (0.794–1.248)	0.968
Sex (male vs. female)	1.124 (0.919–1.376)	0.254	1.157 (0.918–1.458)	0.218
Tumor location (head vs. body/tail)	0.872 (0.717–1.062)	0.872	1.036 (0.825–1.302)	0.760
Stage (III vs. IV)	1.643 (1.278–2.113)	< 0.001	1.438 (1.046–1.976)	0.025
CA19–9, U/mL (≤1000 vs. > 1000)	1.472 (1.204–1.800)	< 0.001	1.416 (1.123–1.785)	0.003
ALB, g/L (≤35 vs. > 35)	0.670 (0.446–1.005)	0.053	0.713 (0.448–1.136)	0.155
ALP, U/L (≤125 vs. > 125)	1.299 (1.049–1.608)	0.016	1.210 (0.955–1.533)	0.114
AAPR (≤0.4 vs. > 0.4)	0.624 (0.512–0.761)	< 0.001	0.599 (0.477–0.753)	< 0.001

Abbreviations: AAPR albumin to alkaline phosphatase ratio, ALB albumin, ALP alkaline phosphatase, CA19–9 carbohydrate antigen 19–9, CI confidence interval, HR hazard ratio, PSM propensity score matching